HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Cogent Biosciences (NASDAQ:COGT) and maintained a $27 price target.
August 30, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cogent Biosciences' stock may see positive movement as HC Wainwright & Co. has reiterated a 'Buy' rating and maintained a $27 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target by a reputable firm like HC Wainwright & Co. is likely to boost investor confidence in Cogent Biosciences, potentially leading to positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100